Product Pipeline

  Phase 1 Phase 2 Phase 3 Filing Approved
AVONEX (INTERFERON BETA-1A)
Multiple Sclerosis, Relapsing forms

AVONEX (Interferon beta-1a) is a leading therapeutic for relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is also approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS.

More Information
X X X X X
TYSABRI (NATALIZUMAB)
Multiple Sclerosis, Relapsing-Remitting

TYSABRI (Natalizumab) has advanced the treatment of MS patients with established efficacy. It has been proven to reduce flare-ups and slow physical disability progression.

More Information
X X X X X
TYSABRI (NATALIZUMAB)
Crohn's Disease (U.S.)
X X X X X
RITUXAN (RITUXIMAB)
Non-Hodgkin's Lymphoma

We collaborate with Genentech on the development and commercialization of RITUXAN.

More Information
X X X X X
RITUXAN (RITUXIMAB)
ANCA-Associated Vasculitis

We collaborate with Genentech on the development and commercialization of RITUXAN.

More Information
X X X X X
RITUXAN (RITUXIMAB)
Anti-TNF Refractory Rheumatoid Arthritis

We collaborate with Genentech on the development and commercialization of RITUXAN.

More Information
X X X X X
RITUXAN (RITUXIMAB)
Chronic Lymphocytic Leukemia

We collaborate with Genentech on the development and commercialization of RITUXAN.

More Information
X X X X X
FUMADERM (FUMARIC ACID ESTERS)
Psoriasis (Germany)

FUMADERM is an oral product containing fumaric acid esters, and was approved in Germany in 1994 for treatment of severe psoriasis. Acquired with the Fumapharm purchase.

X X X X X
FAMPYRA (PROLONGED-RELEASE FAMPRIDINE TABLETS)
Multiple Sclerosis (Walking Ability)

FAMPYRA is an investigational oral, prolonged-release formulation of 4-aminopyridine, that has been developed to improve walking ability in adult patients with multiple sclerosis (MS). Studies have shown that fampridine can increase conduction velocity along damaged nerves, which may result in improved neurological function. This compound is approved in the US (where it is known as AMPYRA) and is being commercialized outside of the US by Biogen Idec under a licensing agreement with Acorda Therapeutics.

X X X X X
TECFIDERA (DIMETHYL FUMARATE)
Multiple Sclerosis, Relapsing Forms

Small molecule immune modulator, oral formation. Acquired with Fumapharm purchase.

X X X X X
GAZYVA (HUMANIZED ANTI-CD20 MAB)
Chronic Lymphocytic Leukemia

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

X X X X X

ALPROLIX is a recombinant factor IX Fc fusion protein for the treatment of hemophilia B. Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development and commercialization of ALPROLIX.

X X X X X

ELOCTATE is a recombinant B-domain deleted factor VIII Fc fusion protein for the treatment of hemophilia A. Biogen Idec and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ELOCTATE.

X X X X X
PLEGRIDY (PEGINTERFERON beta-1a)
Multiple Sclerosis, Relapsing Forms

PLEGRIDY™ (peginterferon beta-1a) is a subcutaneous injectable therapy for relapsing forms of multiple sclerosis (RMS), in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule. PLEGRIDY is a member of the interferon class of treatments for MS.

X X X X X
DACLIZUMAB
Multiple Sclerosis, Relapsing Forms

Humanized antibody specific for IL2 receptor. Daclizumab is being developed under a collaboration agreement with Abbvie Biotherapeutics.

X X X    
TYSABRI (NATALIZUMAB)
Secondary-Progressive MS

 

X X X    
OBINUTUZUMAB (GA101)
Chronic Lymphocytic Leukemia, Front-line (in combination with chlorambucil)

Glycoengineered, type II, humanized anti-CD20 monoclonal antibody. We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

X X X    
OBINUTUZUMAB (GA101)
Diffuse large B-cell lymphoma

Glycoengineered, type II, humanized anti-CD20 monoclonal antibody. We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

X X X    
OBINUTUZUMAB (GA101)
Non-Hodgkin’s Lymphoma, Front-line Indolent

Glycoengineered, type II, humanized anti-CD20 monoclonal antibody. We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

X X X    
OBINUTUZUMAB (GA101)
Non-Hodgkin’s Lymphoma, Refractory Indolent

Glycoengineered, type II, humanized anti-CD20 monoclonal antibody. We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

X X X    
ANTI-TWEAK
Lupus Nephritis

Humanized monoclonal antibody specific for TWEAK.

X X      
Anti-LINGO
Multiple Sclerosis

Anti-LINGO 1 is being investigated for use in multiple sclerosis.

X X      
STX-100
Idiopathic Pulmonary Fibrosis

Novel humanized monoclonal antibody in development for the treatment of idiopathic pulmonary fibrosis (IPF).

X X      
Neublastin
Neuropathic Pain

Neublastin is being investigated for use in neuropathic pain.

X X      
ISIS-SMNrx
Spinal Muscular Atrophy

Antisense investigational drug for the treatment of Spinal Muscular Atrophy (SMA), in development with Isis Pharmaceuticals.

X X      
BAN2401
Alzheimer's Disease

BAN2401 is a humanized monoclonal antibody being developed as a potential treatment for Alzheimer’s disease under a collaboration with Eisai, Co. Ltd.

X X      
CD40L
Systemic Lupus Erythematosus

CD40L is being investigated for use in systemic lupus erythematosus.

X        

BART is being investigated for use in Alzheimer's disease.

X        
E2609
Alzheimer's Disease

E2609 is a BACE inhibitor being developed as a potential treatment for Alzheimer’s disease under a collaboration with Eisai, Co. Ltd.

X